Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...

Pegylated Interferons: Still a Major Player for the Treatment of Myeloproliferative Neoplasms Bispecific antibodies have ushered in a transformative era in treating non–small cell lung cancer (NSCLC), ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified ...

Peluntamig targets DLL3 and CD47, potentially enhancing immune recognition and attack on cancer cells. The SKYBRIDGE study is a phase 1/2 trial assessing peluntamig's safety and efficacy in ...

There are two main types of lung cancer: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Several subtypes exist within these categories, and there are a few other ...

A 56-year-old man presented for 3 weeks of intermittent blurred vision and photophobia.His medical history included type 2 diabetes, hypertension, hyperlipidemia, chronic obstructive pulmonary disease ...

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment ...

3SBio will receive an upfront payment of $1.25B and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8B as well as tiered ...

Please provide your email address to receive an email when new articles are posted on . CAN-2409 plus valacyclovir nearly doubled survival compared with docetaxel for patients who had inadequate ...